Hainan Huluwa Pharmaceutical Group (605199.SH): Pediatric Lung Heat Cough and Asthma Granules are intended to be selected in the fourth batch of the national centralized volume procurement alliance for traditional Chinese medicine.

Hainan Huluwa Pharmaceutical Group (605199.SH) announced that the company participated in the fourth batch of centralized procurement of national traditional Chinese medicine organized by the National Traditional Chinese Medicine Joint Procurement Office (referred to as ""). According to the public announcement of the proposed selection results of the national traditional Chinese medicine alliance centralized volume procurement issued by the Joint Procurement Office on April 30, 2026, the company's pediatric pulmonary fever and cough granules were selected for this centralized procurement. The above-mentioned selected product is one of the company's core main products. The total sales revenue of pediatric pulmonary fever and cough granules in the selected specifications for 2025 is 63.46 million yuan, accounting for 7.04% of the company's operating income in 2025. This centralized procurement is the fourth batch of national traditional Chinese medicine procurement alliance centralized volume procurement organized by the National Traditional Chinese Medicine Joint Procurement Office. During the procurement cycle, medical institutions will prioritize the use of the selected varieties in this centralized procurement and ensure the completion of the agreed purchase quantity. If the company signs a procurement contract and implements it later, it will be beneficial for the company to further expand its in-house sales channels, increase the coverage of the above-mentioned products in various levels of medical institutions, expand the sales scale of related products, increase market share, enhance the market visibility and brand influence of the company's products, and have a certain positive impact on the company's future operational performance.